We are live on ! Find out more
CVAC

CureVac

Delisted

CVAC was delisted on the 5th of January, 2026.

75 hedge funds and large institutions have $26.6M invested in CureVac in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more call options, than puts

Call options by funds: $322K | Put options by funds: $288K

1.46% less ownership

Funds ownership: 4.96%3.5% (-1.5%)

7% less funds holding

Funds holding: 8175 (-6)

19% less capital invested

Capital invested by funds: $32.8M → $26.6M (-$6.2M)

20% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 25

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
75
Holders Change
-6
Holders Change %
-7.41%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
12
Increased
20
Reduced
25
Closed
17
Calls
$322K
Puts
$288K
Net Calls
+$34K
Net Calls Change
-$42K

CVAC Hedge Fund Activity: Q4 2024 in Review

75 institutional investors reported a position in CureVac (CVAC) for Q4 2024, worth a combined $26.6M — down 19% from $32.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CVAC and 12 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 20 added.

The largest buyer was UBS Group, adding an estimated $1.49M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.92M sold.

  • 75 institutional investors held CureVac (CVAC) as of Q4 2024, down from 81 in Q3 2024.
  • Funds reported $26.6M of CureVac stock for Q4 2024, down 19% quarter-over-quarter.
  • 12 funds opened new CureVac positions in Q4 2024 and 17 closed out, a net change of -5 holders.
  • The largest CureVac buyer in Q4 2024 was UBS Group, an estimated $1.49M added.
  • The largest CureVac seller in Q4 2024 was Citadel Advisors, an estimated $2.92M sold.

Based on aggregated 13F filings for Q4 2024.